Concise review: Human pluripotent stem cell-based models for cardiac and hepatic toxicity assessment

Stem Cells

Volumn 29, Issue 5, 2011, Pages 744-748

  Sartipy, Peter ^a   Björquist, Petter ^a  

^a Cellartis AB   (Sweden)

Author keywords

Cardiomyocytes; Differentiation; Drug discovery and development; Hepatocytes; Human pluripotent stem cells; Toxicity testing

Indexed keywords

ROFECOXIB;

ARTICLE; CARDIOTOXICITY; CELL DIFFERENTIATION; CELL THERAPY; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; DRUG SCREENING; EMBRYONIC STEM CELL; HUMAN; LIVER TOXICITY; LONG QT SYNDROME; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL;

DRUG EVALUATION, PRECLINICAL; HEPATOCYTES; HUMANS; MYOCYTES, CARDIAC; PHARMACEUTICAL PREPARATIONS; PLURIPOTENT STEM CELLS; TOXICITY TESTS;

ANIMALIA;

EID: 79955428006     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.631     Document Type: Article

References (35)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-715. (Pubitemid 39173511)
2. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145-1147. (Pubitemid 28516247)
3. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-872. (Pubitemid 350138099)
4. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102. (Pubitemid 40365350)
5. Mitcheson JS, Chen J, Lin M et al. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 2000;97:12329-12333.
6. Echt DS, Liebson PR, Mitchell LB et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-788.
7. van der Heyden MA, Smits ME, Vos MA. Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon? Br J Pharmacol 2008;153:406-409. (Pubitemid 351199028)
8. Altena R, Perik PJ, van Veldhuisen DJ et al. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009;10:391-399.
9. Jonsson MKB, van Veen TAB, Goumans MJ et al. Improvement of cardiac efficacy and safety models in drug discovery by the use of stem cell-derived cardiomyocytes. ExpertOpin Drug Discov 2009;4:357-372.
10. Vidarsson H, Hyllner J, Sartipy P. Differentiation of human embryonic stem cells to cardiomyocytes for in vitro and in vivo applications. Stem Cell Rev 2010;6:108-120.
11. Dick E, Rajamohan D, Ronksley J, Denning C. Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. Biochem Soc Trans 2010;38:1037-1045.
12. Sartiani L, Bettiol E, Stillitano F et al. Developmental changes in cardiomyocytes differentiated from human embryonic stem cells: A molecular and electrophysiological approach. Stem Cells 2007;25:1136-1144. (Pubitemid 46684873)
13. Otsuji TG, Minami I, Kurose Y et al. Progressive maturation in contracting cardiomyocytes derived from human embryonic stem cells: Qualitative effects on electrophysiological responses to drugs. Stem Cell Res 2010;4:201-213.
14. Braam SR, Tertoolen L, van de Stolpe A et al. Prediction of druginduced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res 2010;4:107-116.
15. Jonsson MK, Duker G, Tropp C et al. Quantified proarrhythmic potential of selected human embryonic stem cell-derived cardiomyocytes. Stem Cell Res 2010;4:189-200.
16. Peng S, Lacerda AE, Kirsch GE et al. The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. J Pharmacol Toxicol Methods 2010;61:277-286.
17. Andersson H, Steel D, Asp J et al. Assaying cardiac biomarkers for toxicity testing using biosensing and cardiomyocytes derived from human embryonic stem cells. J Biotechnol 2010;150:175-181.
18. Rodriguez-Antona C, Donato MT, Boobis A et al. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: Molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 2002;32:505-520. (Pubitemid 34743622)
19. Butura A, Johansson I, Nilsson K et al. Differentiation of human hepatoma cells during confluence as revealed by gene expression profiling. Biochem Pharmacol 2004;67:1249-1258. (Pubitemid 38315090)
20. Czyz J, Wiese C, Rolletschek A et al. Potential of embryonic and adult stem cells in vitro. Biol Chem 2003;384:1391-1409. (Pubitemid 37508643)
21. Hay DC, Fletcher J, Payne C et al. Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling. Proc Natl Acad Sci USA 2008;105:12301-12306.
22. Brolen G, Sivertsson L, Bjorquist P et al. Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage. J Biotechnol 2010;145:284-294.
23. Hay DC, Pernagallo S, Diaz-Mochon JJ et al. Unbiased screening of polymer libraries to define novel substrates for functional hepatocytes with inducible drug metabolism. Stem Cell Res 2011;6: 92-102.
24. Song Z, Cai J, Liu Y et al. Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. Cell Res 2009;19: 1233-1242.
25. Sullivan GJ, Hay DC, Park IH et al. Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology 2010;51:329-335.
26. Ghodsizadeh A, Taei A, Totonchi M et al. Generation of liver disease-specific induced pluripotent stem cells along with efficient differentiation to functional hepatocyte-like cells. Stem Cell Rev 2010;6: 622-632.
27. Rashid ST, Corbineau S, Hannan N et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest 2010;120:3127-3136.
28. Jensen J, Hyllner J, Bjorquist P. Human embryonic stem cell technologies and drug discovery. J Cell Physiol 2009;219:513-519.
29. McKernan R, McNeish J, Smith D. Pharma's developing interest in stem cells. Cell Stem Cell 2010;6:517-520.
30. Urnov FD, Rebar EJ, Holmes MC et al. Genome editing with engineered zinc finger nucleases. Nat Rev Genet 2010;11:636-646.
31. Buecker C, Chen HH, Polo JM et al. A murine ESC-like state facilitates transgenesis and homologous recombination in human pluripotent stem cells. Cell Stem Cell 2010;6:535-546.
32. Moretti A, Bellin M, Welling A et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010;363: 1397-1409.
33. Itzhaki I, Maizels L, Huber I et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011;471:225-229.
34. Minor LK. Label-free cell-based functional assays. Comb Chem High Throughput Screen 2008;11:573-580.
35. Barbaric I, Gokhale PJ, Andrews PW. High-content screening of small compounds on human embryonic stem cells. Biochem Soc Trans 2010;38:1046-1050.